Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia

Inclusion Criteria:

* Diagnosis of acute myeloid leukemia (AML) meeting 1 of the following criteria:

  * Primary refractory disease (no complete response \[CR\] after ≥ 2 induction therapies)
  * Relapsed disease not in CR after ≥ 1 course of standard reinduction therapy
  * Secondary AML from myelodysplastic syndromes
  * Disease relapsed ≥ 2 months after transplant and no option of donor lymphocyte infusions (e.g., recipients of autologous or umbilical cord blood transplants)
  * Chronic myelogenous leukemia with myeloid blast crisis not in second chronic phase after at least one cycle of standard chemotherapy and imatinib
  * Over 60 years of age with relapse within 6 months after completion of last chemotherapy
  * Over 60 years of age with blast count \< 30% within 10 days before study entry
* Related HLA-haploidentical natural killer cell donor available
* No severe organ damage (by clinical or laboratory assessment)
* Performance status 50-100%
* No evidence of active infection on chest X-ray
* No active fungal infection

Exclusion Criteria:

* Active central nervous system (CNS) leukemia
* Pleural effusions large enough to be detectable by chest x-ray
* Pregnant or nursing (positive pregnancy test)
* Fertile patients must use effective contraception
* Less than 60 days since prior transplant
* Less than 3 days since prior prednisone
* Less than 3 days since other prior immunosuppressive medication